Dermatological complications and safety of anti-TNF treatments.
Kerbleski
Joseph F
JF
Department of Dermatology, Tufts Medical Center, Boston, MA 02111, USA. JKerbleski@tuftsmedicalcenter.org
Gottlieb
Alice B
AB
D018501:Antirheumatic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects; D007275:Injections, Intravenous / Q000009:adverse effects; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D009894:Opportunistic Infections / Q000139:chemically induced; D011565:Psoriasis / Q000139:chemically induced; D012874:Skin Diseases, Infectious / Q000139:chemically induced; D012878:Skin Neoplasms / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha